AltraVue Capital’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-3,797,813
Closed -$46.9M 28
2024
Q4
$46.9M Hold
3,797,813
3.91% 9
2024
Q3
$43.2M Buy
3,797,813
+402,550
+12% +$4.04M 3.89% 11
2024
Q2
$24.2M Buy
3,395,263
+239,343
+8% +$1.83M 2.41% 16
2024
Q1
$21.1M Buy
3,155,920
+181,587
+6% +$1.25M 2.29% 16
2023
Q4
$19.3M Sell
2,974,333
-34,856
-1% -$225K 2.23% 19
2023
Q3
$28.4M Sell
3,009,189
-721,782
-19% -$8.69M 3.38% 15
2023
Q2
$52.1M Buy
3,730,971
+15,090
+0.4% +$257K 6.13% 4
2023
Q1
$69.7M Buy
3,715,881
+412,921
+13% +$6.78M 8.37% 1
2022
Q4
$45.5M Buy
3,302,960
+618,000
+23% +$9.47M 6.37% 3
2022
Q3
$51.3M Sell
2,684,960
-50,280
-2% -$916K 7.68% 2
2022
Q2
$41.7M Buy
2,735,240
+481,874
+21% +$7.13M 6.14% 3
2022
Q1
$45.9M Buy
2,253,366
+270
+0% +$5.5K 6.24% 3
2021
Q4
$65.7M Sell
2,253,096
-211,220
-9% -$6.04M 8.7% 1
2021
Q3
$53.2M Buy
2,464,316
+277,360
+13% +$6.7M 7.86% 1
2021
Q2
$56.1M Sell
2,186,956
-153,244
-7% -$3.27M 9.94% 1
2021
Q1
$42.7M Buy
2,340,200
+92,405
+4% +$1.54M 9.44% 1
2020
Q4
$25.9M Sell
2,247,795
-70,235
-3% -$642K 7.73% 1
2020
Q3
$17.7M Buy
2,318,030
+384,215
+20% +$2.91M 8.25% 1
2020
Q2
$12.7M Sell
1,933,815
-16,540
-0.8% -$92.3K 9.52% 2
2020
Q1
$9.97M Sell
1,950,355
-261,087
-12% -$1.58M 8.23% 4
2019
Q4
$17M Sell
2,211,442
-11,940
-0.5% -$69.7K 8.43% 1
2019
Q3
$11.8M Buy
2,223,382
+114,570
+5% +$711K 6.48% 2
2019
Q2
$11.8M Buy
2,108,812
+133,337
+7% +$550K 6.53% 2
2019
Q1
$8.4M Buy
1,975,475
+655,507
+50% +$2.67M 4.75% 4
2018
Q4
$5.41M Buy
+1,319,968
New +$6.89M 3.4% 7

Other funds holding CDMO

AltraVue Capital's CDMO Position: Q1 2025 in Review

AltraVue Capital sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q1 2025, closing a stake of 3,797,813 shares — an estimated $46.9M sold.

AltraVue Capital first reported a position in CDMO in Q4 2018 and held it in 25 quarters. The position peaked at $69.7M in Q1 2023. 2 funds tracked by Wall St. Rank hold CDMO as of Q1 2025.

  • AltraVue Capital reported no remaining Avid Bioservices, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • AltraVue Capital sold 3,797,813 Avid Bioservices, Inc. Common Stock shares in Q1 2025, an estimated $46.9M.
  • AltraVue Capital first reported a position in Avid Bioservices, Inc. Common Stock in Q4 2018 and held it in 25 quarters.
  • AltraVue Capital's Avid Bioservices, Inc. Common Stock position peaked at $69.7M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q1 2025.

Based on AltraVue Capital's 13F filing for Q1 2025, filed 13 May 2025.